Author

Thomas D. Southgate

Observed name: Thomas Southgate

Institution: GlaxoSmithKline (United Kingdom)

Observed institutions: Cedars-Sinai Medical Center, University of California, Los Angeles, GlaxoSmithKline (United Kingdom), Cancer Research UK, University of Manchester, Cancer Research UK Manchester Institute, The Christie Hospital, The Christie NHS Foundation Trust

OpenAlex ID: A5110025561

E-Cadherin Inhibits Cell Surface Localization of the Pro-Migratory 5T4 Oncofetal Antigen in Mouse Embryonic Stem Cells

2007 · Helen L. Spencer, Angela M. Eastham, et al. · Molecular Biology of the Cell · 114

Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors

2000 · Thomas D. Southgate, Paul A. Kingston, et al. · Current Protocols in Neuroscience · 63

CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells

2010 · Thomas D. Southgate, Owen J. McGinn, et al. · PLoS ONE · 56

Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors

2008 · Thomas Southgate, Kurt M. Kroeger, et al. · Current Protocols in Neuroscience · 36

The P140K mutant of humanO6-methylguanine-DNA-methyltransferase (MGMT) confers resistancein vitro andin vivo to temozolomide in combination with the novel MGMT inactivatorO6-(4-bromothenyl)guanine

2005 · Lorna B. Woolford, Thomas D. Southgate, et al. · The Journal of Gene Medicine · 31

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)

2009 · Eyad Elkord, Adam Dangoor, et al. · Cancer Immunology Immunotherapy · 30

Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase

2006 · Thomas D. Southgate, Victoria Sheard, et al. · The Journal of Gene Medicine · 23

The role of small molecules in cell and gene therapy

2020 · Lewis L. Brayshaw, Carlos Martinez-Fleites, et al. · RSC Medicinal Chemistry · 21

A Cancer Cell-Specific Inducer of Apoptosis

2007 · Katie L. Green, Craig Brown, et al. · Human Gene Therapy · 18

Adenoviruses Encoding HPRT Correct Biochemical Abnormalities of HPRT-Deficient Cells and Allow Their Survival in Negative Selection Medium

1999 · Thomas D. Southgate, Derek Bain, et al. · Metabolic Brain Disease · 16

Hypoxia response element‐driven cytosine deaminase/5‐fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cellsin vitro

2008 · Laure Marignol, Ruth Foley, et al. · The Journal of Gene Medicine · 13

Hypoxia‐targeted over‐expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT‐11)

2007 · Torkjel Matzow, Rachel L. Cowen, et al. · The Journal of Gene Medicine · 13

Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours

2001 · Maria G. Castro, Thomas Southgate, et al. · Trends in Endocrinology and Metabolism · 13

Dual agent chemoprotection by retroviral co‐expression of either MDR1 or MRP1 with the P140K mutant of O6‐methylguanine‐DNA‐methyl transferase

2006 · Thomas D. Southgate, Elloise Garside, et al. · The Journal of Gene Medicine · 11

Chapter 33 Gene therapy for inherited neurological disorders: Towards therapeutic intervention in the Lesch-Nyhan syndrome

1998 · Pedro R. Lowenstein, Thomas D. Southgate, et al. · Progress in brain research · 11

Oncofetal Antigen

2008 · Thomas D. Southgate, Peter L. Stern · Springer eBooks · 1

Genetic manipulation of drug sensitivity in haematopoietic cells

2004 · Thomas Southgate, Leslie J. Fairbairn · Expert Reviews in Molecular Medicine · 1

Retrovirally-mediated genetic correction of mesenchymal stem cells from patients affected by mucopolysaccharidosis type II (Hunter Syndrome)

2008 · Carla Corradi-Perini, Thomas D. Southgate, et al.

669. Drug Selection of Hematopoietic Cells by Regulated MGMT Activity

2006 · Barbara Verbeek, Thomas D. Southgate, et al. · Molecular Therapy

Works count: 20

Citation count: 471

H-index: 13

I10-index: 15